Sept. 10, 2026 — Artificial intelligence is accelerating drug discovery and changing how pharmaceutical companies plan manufacturing capacity, creating new demands for facility designers, builders and owners. PCL Construction is highlighting how faster development cycles are prompting biopharmaceutical manufacturers to rethink facility speed, flexibility and digital capabilities.
AI-powered platforms can analyze large biological datasets and help researchers identify potential drug candidates earlier in the development process. As more therapies move through development, manufacturers are facing pressure to establish production capacity while maintaining strict quality and regulatory requirements.
The shift is also contributing to increased investment in U.S. pharmaceutical manufacturing capacity, creating opportunities for new facilities as well as modernization of existing assets.
Shorter research and development timelines are compressing the period available for owners to plan manufacturing facilities. Facility decisions increasingly need to advance while pharmaceutical candidates are still being evaluated.
That environment is encouraging greater use of modular construction, prefabricated utility systems and collaborative project delivery. Site selection, permitting, utility planning and process design can be coordinated earlier and advanced concurrently to help reduce overall project timelines.
For construction teams, the change means project planning needs to account for manufacturing requirements earlier in the development process. Early coordination can help owners identify infrastructure needs and address potential constraints before construction progresses.
AI can accelerate drug discovery, but it does not eliminate uncertainty over which therapies will ultimately reach commercial production. Manufacturers therefore need facilities that can adapt as product portfolios and production requirements change.
Flexible manufacturing environments can include expansion-ready utilities, modular systems and open manufacturing layouts that allow equipment and production configurations to be changed over time.
Pilot plants and process development facilities are also becoming more important as manufacturers evaluate production processes before committing to commercial-scale capacity. Flexible spaces can allow multiple programs to advance without requiring a dedicated production line for each potential product.
This approach can help owners manage capital investment while maintaining options for future production changes.
Digital technologies are becoming another core consideration for biopharmaceutical construction. Digital twins, predictive analytics and real-time data systems can support equipment monitoring, operational performance and facility management.
As these technologies become more integral to pharmaceutical operations, data architecture and operational technology requirements need to be considered earlier in design rather than added near project completion.
PCL is incorporating digital twin-enabled documentation into commissioning and closeout processes, giving owners a more detailed digital record as facilities transition into operations.
The acceleration of pharmaceutical research is creating new construction requirements for speed, adaptability and digital readiness. Owners developing biopharmaceutical facilities may need to make capital planning decisions earlier while also designing buildings that can accommodate changing products and manufacturing strategies.
For contractors and design teams, the trend increases the importance of early collaboration, modular delivery, flexible infrastructure and digital systems that can support facilities throughout their operating life.
Source: PCL Construction.
